TNFAIP3基因遗传变异对食管鳞癌患者预后的影响

doi:10.12092/j.issn.1009-2501.2018.07.016

摘要/Abstract

摘要：

目的: 探讨重组人肿瘤坏死因子α诱导蛋白3（TNFAIP3）基因的遗传变异对食管鳞癌（ESCC）患者预后的影响。方法: 本研究纳入175例食管鳞癌根治术患者。在手术前收集患者的外周血5 mL用来提取基因组DNA，对rs583522位点进行基因分型，并对基因型和基线临床资料，以及患者的长期预后情况进行关联性分析。结果: 野生型AA型相对于AG/GG型患者者来说具有明显较晚的肿瘤分期（P<0.001）。AA型的患者更容易复发（P=0.022）。生存分析结果表明AA型患者相对于AG/GG型患者具有明显较差的总生存期（OS），两种基因型患者的中位OS分别为38.2和48.5个月（P=0.017）。结论: TNFAIP3多态性位点rs583522可能通过影响了该基因的功能，进而使得不同基因型的ESCC患者具有不同的恶性程度。因此TNFAIP3基因rs583522位点可以作为评价食管鳞癌患者预后的生物标记物。

关键词: 食管鳞癌, 重组人肿瘤坏死因子α诱导蛋白3, 多态性, 预后

Abstract:

AIM: To investigate the influence of genetic variation of tumor necrosis factor alpha induced protein 3 (TNFAIP3) on prognosis among esophageal squamous cell carcinoma patients. METHODS: A total of 175 patients underwent complete surgical resection of esophageal squamous cell carcinoma were included in this study. 5 mL peripheral blood specimen of the patient was collected. Genomic DNA were extracted and genotype of rs583522 were analyzed. The association between genotype and baseline clinical characteristics and prognosis were analyzed. RESULTS: Wild type AA genotypes showed advanced tumor stages compared with those of homozygous G-allele carriers (P<0.001). Patients with an AA genotype were significantly more likely to experience relapse (P=0.022). Survival analysis revealed a significant difference in overall survival between different genotype groups (P=0.017). CONCLUSION: rs583522 genotypes can be used as biomarkers to evaluate the prognosis of patients with esophageal squamous carcinoma.

Key words: esophageal squamous carcinoma, TNFAIP3, polymorphism, prognosis

中图分类号:

R968

单艳，李志刚. TNFAIP3基因遗传变异对食管鳞癌患者预后的影响[J]. 中国临床药理学与治疗学, 2018, 23(7): 820-824.

SHAN Yan, LI Zhigang. Influence of genetic variation of TNFAIP3 on prognosis among esophageal squamous cell carcinoma patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 820-824.

参考文献

［1］Naik KB, Liu Y, Goodman M, et al. Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base［J］.Cancer, 2017, 123(18): 3476-3485.

［2］Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］.CA Cancer J Clin, 2016, 66(2): 115-32.

［3］Liang H, Fan JH, Qiao YL.Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China［J］. Cancer Biol Med, 2017, 14(1): 33-41.

［4］Peerlings J, Van De Voorde L, Mitea C, et al.Hypoxia and hypoxia response-associated molecular markers in esophageal cancer: A systematic review［J］. Methods, 2017, 130: 51-62.

［5］Yang Y, Jia J, Sun Z, et al. Prognosis impact of clinical characteristics in patients with inoperable esophageal squamous cell carcinoma［J］.PLoS One, 2017, 12(8): e0182660.

［6］Chang JS, Hsiao JR, Chen CH.ALDH2 polymorphism and alcohol-related cancers in Asians: a public health perspective［J］.J Biomed Sci, 2017, 24(1): 19.

［7］Shimane K, Kochi Y, Horita T, et al.The association of a nonsynonymous single-nucleotide polymorphism in TNFAIP3 with systemic lupus erythematosus and rheumatoid arthritis in the Japanese population［J］. Arthritis Rheum, 2010, 62(2): 574-579.

［8］Jallades L, Baseggio L, Sujobert P, et al.Exome sequencing identifies recurrent BCOR gene alterations and the absence of KLF2, TNFAIP3 and MYD88 mutations in splenic diffuse red pulp small B-cell lymphoma［J］. Haematologica, 2017，102(10):1758-1766.

［9］Osako M, Itsumi M, Yamaguchi H, et al.A20 restores phorbol ester-induced differentiation of THP-1 cells in the absence of nuclear factor-kappaB activation［J］.J Cell Biochem, 2018，119(2):1475-1487.

［10］Ghadban T, Schmidt-Yang M, Uzunoglu FG, et al.An A/C germline single-nucleotide polymorphism in the TNFAIP3 gene is associated with advanced disease stage and survival in only surgically treated esophageal cancer［J］.J Hum Genet, 2014, 59(12): 661-666.

［11］Plant D, Prajapati R, Hyrich KL, et al. Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort［J］. Arthritis Rheum, 2012, 64(3): 665-670.

［12］Takahashi Y, Sugimachi K, Yamamoto K, et al.Japanese genome-wide association study identifies a significant colorectal cancer susceptibility locus at chromosome 10p14［J］.Cancer Sci,2017， 108(11):2239-2247.

［13］Tang H, Wei P, Chang P, et al.Genetic polymorphisms associated with pancreatic cancer survival: a genome-wide association study［J］. Int J Cancer, 2017, 141(4): 678-686.

［14］Foti A, Dorendorf F, Leimkuhler S.Single nucleotide polymorphism causes enhanced radical oxygen species production by human aldehyde oxidase［J］. PLoS One, 2017, 12(7): e0182061.

［15］Zhang X, Yin JF, Zhang J, et al.UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis［J］.Cancer Chemother Pharmacol, 2017, 80(1): 135-149.

［16］楼江, 林能明, 王刚，等.吉西他滨的核苷酸转运体基因组学研究［J］.中国临床药理学与治疗学, 2016,22 (5): 586-594.

［17］Ghadban T, Schmidt-Yang M, Uzunoglu FG, et al.Evaluation of the germline single nucleotide polymorphism rs583522 in the TNFAIP3 gene as a prognostic marker in esophageal cancer［J］.Cancer Genet, 2015, 208(12): 595-601.

［18］Lurje G, Leers JM, Pohl A, et al.Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus［J］. Ann Surg, 2010, 251(5): 857-864.

［19］Adrianto I, Wen F, Templeton A, et al.Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus［J］. Nat Genet, 2011, 43(3): 253-258.

[1]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[2]	朱丽, 魏兵, 廖世峨, 张超, 郑晓宇, 刘亚军. 药物代谢酶细胞色素P450单核苷酸多态性影响哮喘儿童吸入皮质醇激素疗效研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 536-543.
[3]	石大伟, 郑晓永, 靳晓丹, 赵晓曼, 陈杰, 杜幸军. XPC基因多态性rs2228001对接受卡培他滨为基础辅助化疗的结直肠癌患者预后的影响[J]. 中国临床药理学与治疗学, 2023, 28(4): 391-399.
[4]	周晶, 周琛, 廖珂, 邱爱林, 董巍檑, 郭紫芬. 孕激素受体基因G1978T 多态性与子宫内膜癌的相关性研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 400-406.
[5]	张志英, 靳秀红, 张小宁, 张向峰, 罗青林, 张松林. TBX21和ADCY9多态性在儿童哮喘发生发展中的临床研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 407-412.
[6]	黄凯歌, 许勤华, 王伟. 血糖、血钙对急性重症胰腺炎患者预后影响的交互作用及预测效能研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1227-1234.
[7]	刘璐, 石雨菲, 何庆烽, 徐凤艳, 王鲲, 蔡卫民, 相小强. 群体模型分析方法评估基因多态性对药物PK/PD的影响[J]. 中国临床药理学与治疗学, 2023, 28(11): 1275-1282.
[8]	黄小明, 杜野, 林少明, 沈观乐. 呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 66-74.
[9]	王爽, 刘嘉, 张月丽. POR*28基因多态性与中国肾移植患者他克莫司稳定剂量的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(9): 991-997.
[10]	付虹, 田磊. 缺血性脑卒中伴高血压病患者个体化精准治疗的研究[J]. 中国临床药理学与治疗学, 2022, 27(8): 870-876.
[11]	陈文刚, 殷勤, 张巍巍, 周露露, 寇婉青, 袁小龙. 皖南地区高血压患者MTHFR基因多态性分布及与血Hcy相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 768-774.
[12]	武元竹, 刘俊, 杨魁, 彭静, 栾家杰, 韦俊, 张大发, 宋帅, 袁小龙, 王中方, 张年宝, 解丹, 姜鹏, 范洁. 安徽地区汉族人群CYP2C9*3和VKORC1-1639G>A基因多态性分布及对华法林稳定剂量的影响[J]. 中国临床药理学与治疗学, 2022, 27(6): 652-659.
[13]	陈佳音, 王丽, 王立军, 童刚领, 马洁, 陈西敬, 卢杨. 有机阳离子转运体基因多态性与奥沙利铂毒性及疗效的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(2): 171-177.
[14]	刘乐, 齐文博, 白玉萍, 刘乾, 尹振宇, 李晓梅, 俞阳, 陈昊. 胃癌PD-1/PD-L1免疫检查点抑制剂免疫治疗影响因素分析[J]. 中国临床药理学与治疗学, 2022, 27(1): 95-101.
[15]	周敏敏, 余露, 韩超, 顾达民, 雷道赟. 人类胆固醇酯转移蛋白rs5882基因多态性与围术期神经认知功能紊乱的相关性[J]. 中国临床药理学与治疗学, 2021, 26(7): 768-774.